J Neuroimmunol

1. MARQUES RF, Pedrosa DA, Talim N, Lemos JC, et al
   Relapsing-remitting multiple sclerosis as a potential consequence of thalidomide treatment: A case report.
   J Neuroimmunol. 2025;404:578606.
   

   >> Share

   
   

   
   J Neurol

2. LEAVITT V, Mostert J, Comtois J, Moral E, et al
   Measuring cognitive change in secondary progressive MS: an analysis of the ASCEND cognition substudy.
   J Neurol. 2025;272:338.
   

   >> Share

   
   

   
   J Neurol Sci

3. KELLY H, Sun R, Elkasaby M, Wang A, et al
   Movement disorders in relapsing and progressive MS: A comprehensive prospective evaluation of a large real-life cohort.
   J Neurol Sci. 2025;472:123468.
   

   >> Share

   
   

   
   Mult Scler

4. MARRIE RA, Bolton JM, Ling V, Bernstein CN, et al
   Risk factors for incident peripartum mental illness in multiple sclerosis.
   Mult Scler. 2025 Apr 18:13524585251330109. doi: 10.1177/13524585251330109.
   

   >> Share

   
   
5. MACARON G, Farah N, Charbonneau S, Morrow SA, et al
   Addressing patient-reported cognitive impairment in multiple sclerosis clinical practice: A challenging endeavor.
   Mult Scler. 2025 Apr 18:13524585251334488. doi: 10.1177/13524585251334488.
   

   >> Share

   
   
6. FADLALLAH Y, Wang Y, Malik MT, Tian F, et al
   Frequency and potential risk factors associated with the development of asymptomatic T2 hyperintense cervical spine lesions on MRI in patients with relapsing-remitting multiple sclerosis.
   Mult Scler. 2025 Apr 17:13524585251331405. doi: 10.1177/13524585251331405.
   

   >> Share

   
   
7. JENSEN MP, Robles S, Nash MG, May S, et al
   Hypnosis and mindfulness audio recordings for reducing fatigue in individuals with multiple sclerosis: A randomized controlled study.
   Mult Scler. 2025 Apr 17:13524585251329820. doi: 10.1177/13524585251329820.
   

   >> Share

   
   
8. EL AYOUBI NK, Bal MN, Metri N, El Sammak S, et al
   Slower retinal thinning over a year predicts continuous NEDA status at follow-up in multiple sclerosis: A longitudinal OCT study.
   Mult Scler. 2025 Apr 12:13524585251332499. doi: 10.1177/13524585251332499.
   

   >> Share

   
   
9. BSTEH G, Hegen H, Albrecht P, Havla J, et al
   Emphasizing complementary in "Investigating the complementary value of OCT to MRI in cognitive impairment in relapsing-remitting multiple sclerosis".
   Mult Scler. 2025 Apr 12:13524585251329800. doi: 10.1177/13524585251329800.
   

   >> Share

   
   
10. CHRISTENSEN R, Jolly A, Yam C, Yiannakas MC, et al
    Response to letter to the editor: 'Investigating the complementary value of OCT to MRI in cognitive impairment in relapsing-remitting multiple sclerosis'.
    Mult Scler. 2025 Apr 12:13524585251329787. doi: 10.1177/13524585251329787.
    

    >> Share

    
    

    
    Neurology

11. NEWSOME SD, Krzystanek E, Selmaj KW, Dufek M, et al
    Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study.
    Neurology. 2025;104:e213574.
    

    >> Share

    
    
12. GUINEBRETIERE O, Pierret C, Calonge Q, Januel E, et al
    Updated Multiple Sclerosis Incidence in France, 2011-2021.
    Neurology. 2025;104:e213586.
    

    >> Share

    
    

    
    PLoS One

13. SCHLAEGER S, Muhlau M, Gilbert G, Vavasour I, et al
    Sensitivity of multi-parametric quantitative magnetic resonance imaging for multiple sclerosis pathology.
    PLoS One. 2025;20:e0318415.
    

    >> Share

    
    

    
    Rev Neurol (Paris)

14. KETATA I, Ellouz E, Ketata A
    Psychoses onset in multiple sclerosis: A systematic review and meta-analysis.
    Rev Neurol (Paris). 2025 Apr 15:S0035-3787(25)00497.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share